BPC-157: a review of preclinical research

BPC-157 is one of the most discussed peptides in preclinical literature. Interest in it has centred on in vitro work and animal models, mainly in connective tissue, the gastrointestinal tract and the formation of new blood vessels. This review sets out what has been studied, which mechanisms have been proposed and where the available data stop. We write about laboratory findings, not about use in people.

Where BPC-157 comes from

The peptide is a fragment of a longer protein found in gastric juice, which is why its origin is often described as natural. The compound used in research is produced by chemical synthesis, and that matters: a synthetic route lets the composition be controlled and verified batch by batch. The name BPC appears in the literature as shorthand for Body Protection Compound.

Sequence and structure

BPC-157 is made of 15 amino acid residues. Its sequence, written in one-letter code, is GEPPPGKPADDAGLV. The molecular weight is roughly 1.4 kDa, far smaller than a typical protein. A short chain is easier to synthesise and analyse, but it also demands strict verification. Small synthesis by-products, such as truncated or extended sequences, can change an experimental result.

Stability in the laboratory

Peptides in solution are prone to hydrolysis and oxidation, so their form and storage conditions matter a great deal. A lyophilised powder is generally more stable than a solution. Good laboratory practice includes:

• storing the lyophilised material cold, dark and dry,
• limiting repeated freeze-thaw cycles,
• checking purity by HPLC before starting a series of experiments,
• confirming molecular mass by mass spectrometry (MS).

These steps help you tell a biological change apart from a change caused by degradation of the material.

Animal models: what has been reported

Most of the data on BPC-157 comes from animal studies. Three areas come up most often.

Tendons and ligaments

In animal models of tendon and ligament injury, researchers have described better organised collagen fibres and faster restoration of tissue structure compared with control groups. Such models allow healing processes to be studied under controlled conditions, but applying the findings to other species needs separate verification.

The gastrointestinal tract

The second, very widely described context is the lining of the stomach and intestine. In models of damage caused by irritating agents and in models of intestinal inflammation, changes in mucosal structure and in inflammatory markers have been observed. This body of work is the basis for most reviews of the peptide.

Angiogenesis

The third area concerns the growth of new blood vessels. In vitro work, for example in endothelial cell cultures, has looked at effects on cell migration and organisation. Results from animal models pointed in a similar direction, which makes angiogenesis one of the more closely examined topics.

Proposed mechanisms

The mechanism of action of BPC-157 is not fully explained. The literature offers several hypotheses, and each remains an active area of study.

The VEGFR2 pathway

One proposed route involves VEGFR2, the vascular endothelial growth factor receptor. Some authors suggest the peptide could modulate signalling through this pathway, which would fit the observed effects on angiogenesis. These are, however, hypotheses based mainly on in vitro work and they have not been firmly confirmed.

Nitric oxide (NO)

A second hypothesis concerns the nitric oxide system. Nitric oxide helps regulate vascular tone, and some animal models have reported changes in its levels or in the activity of the enzymes that produce it under experimental conditions. The link between those changes and the tissue-level effects is still open.

What has been studied: summary

Research area	Model type	Most often reported direction
Tendons and ligaments	Animals, mechanical injury	Better tissue organisation
Gastrointestinal tract	Animals, injury and inflammation	Changes in mucosa and inflammatory markers
Angiogenesis	In vitro and animals	Effects on cell migration and vessel formation
Mechanisms	In vitro	Hypotheses: VEGFR2, NO system

Limits of the evidence

An honest review has to name the weak points. The most important are:

• the data come mainly from animal models and in vitro studies,
• high-quality, methodologically rigorous publications are fewer than preliminary reports,
• many results come from single research groups, which makes independent replication harder,
• clinical data are limited and do not support conclusions about effectiveness.

BPC-157 has no registered drug form in most countries. For a researcher, that means it is treated as a subject of study, and every interpretation of a result calls for controls, replication and reference to the wider literature.

BPC-157 and TB-500 in research

The two peptides are sometimes compared, because researchers often plan them within the same programme. They differ in origin and structure.

Feature	BPC-157	TB-500
Origin	Fragment of a protein found in gastric juice	Synthetic fragment of thymosin beta-4
Structure	15 amino acid residues	Short fragment with a different sequence
Main research area	Connective tissue, gut, blood vessels	Cell migration and actin dynamics

The BPC-157 TB-500 set lets you prepare both compounds in one order, which simplifies planning comparative series. BPC-157 is also available on its own.

Laboratory practice

Reconstitute the lyophilised powder in the solvent named on the product sheet, keeping to the basic rules for handling biologically active material: add liquid slowly down the vial wall, avoid vigorous shaking, and move the solution to cold storage promptly. When preparing working solutions, the concentration calculator converts mass into molar concentration and volume.

Every MOLEVIA batch carries a purity of at least 99%, confirmed by HPLC, and a mass confirmed by MS. We describe our testing procedures on the quality page.

Shipping and orders

Orders placed by 14:00 on a business day ship the same day. Within Poland, parcels go to an InPost Paczkomat with next business day delivery. We ship to 29 European countries by DPD, with delivery in 2-4 business days. Free delivery from 75 EUR, 65 GBP, 80 USD. Full details are on the shipping page.

Key takeaways

• BPC-157 is a 15-residue peptide derived from a fragment of a protein found in gastric juice.
• Most data comes from animal models and in vitro work covering connective tissue, the gut and angiogenesis.
• Mechanisms such as the VEGFR2 pathway and the nitric oxide system remain hypotheses that need further verification.
• Stability depends on form, temperature and protection from light and moisture.
• Credible research requires HPLC purity and MS mass confirmation for every batch.
• MOLEVIA sells BPC-157 exclusively as a Research Use Only (RUO) reagent.